Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Experimentally guided computational antibody affinity maturation with de novo docking, modelling and rational design.

Cannon DA, Shan L, Du Q, Shirinian L, Rickert KW, Rosenthal KL, Korade M 3rd, van Vlerken-Ysla LE, Buchanan A, Vaughan TJ, Damschroder MM, Popovic B.

PLoS Comput Biol. 2019 May 1;15(5):e1006980. doi: 10.1371/journal.pcbi.1006980. eCollection 2019 May.

2.

Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions.

Du Q, Damschroder M, Pabst TM, Hunter AK, Wang WK, Luo H.

MAbs. 2019 May/Jun;11(4):789-802. doi: 10.1080/19420862.2019.1599634. Epub 2019 Apr 14.

PMID:
30913985
3.

Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy.

Varkey R, Du Q, Karnell JL, Xiao X, Casey KA, Woods R, Rosenthal K, Wilson S, Dall'Acqua WF, Wu H, Herbst R, Ettinger R, Damschroder M.

PLoS One. 2019 Jan 25;14(1):e0211236. doi: 10.1371/journal.pone.0211236. eCollection 2019.

4.

Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.

Shan L, Mody N, Sormani P, Rosenthal KL, Damschroder MM, Esfandiary R.

Mol Pharm. 2018 Dec 3;15(12):5697-5710. doi: 10.1021/acs.molpharmaceut.8b00867. Epub 2018 Nov 15.

PMID:
30395473
5.

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody.

Oganesyan V, Peng L, Bee JS, Li J, Perry SR, Comer F, Xu L, Cook K, Senthil K, Clarke L, Rosenthal K, Gao C, Damschroder M, Wu H, Dall'Acqua W.

J Biol Chem. 2018 Jun 1;293(22):8439-8448. doi: 10.1074/jbc.M117.818013. Epub 2018 Apr 18.

6.

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA.

Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15.

7.

Molecular basis for the mechanism of action of an anti-TACE antibody.

Peng L, Cook K, Xu L, Cheng L, Damschroder M, Gao C, Wu H, Dall'Acqua WF.

MAbs. 2016 Nov/Dec;8(8):1598-1605. Epub 2016 Sep 9.

8.

Targeting CD73 in the tumor microenvironment with MEDI9447.

Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham NM, Leow CC, Diedrich G, Damschroder M, Herbst R, Hollingsworth RE, Sachsenmeier KF.

Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug.

9.

Generation and Characterization of an IgG4 Monomeric Fc Platform.

Shan L, Colazet M, Rosenthal KL, Yu XQ, Bee JS, Ferguson A, Damschroder MM, Wu H, Dall'Acqua WF, Tsui P, Oganesyan V.

PLoS One. 2016 Aug 1;11(8):e0160345. doi: 10.1371/journal.pone.0160345. eCollection 2016.

10.

Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering.

Geoghegan JC, Fleming R, Damschroder M, Bishop SM, Sathish HA, Esfandiary R.

MAbs. 2016 Jul;8(5):941-50. doi: 10.1080/19420862.2016.1171444. Epub 2016 Apr 6.

11.

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.

Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, Dall'Acqua WF, Damschroder MM.

MAbs. 2016;8(3):454-67. doi: 10.1080/19420862.2016.1143182. Epub 2016 Feb 8.

12.

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody.

Peng L, Damschroder MM, Cook KE, Wu H, Dall'Acqua WF.

MAbs. 2016;8(1):163-75. doi: 10.1080/19420862.2015.1113359.

13.

A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.

Rios-Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, Cheng L, Du Q, Schifferli K, Rothstein R, Leow CC, Heidbrink-Thompson J, Jin X, Gao C, Friedman J, Wilkinson B, Damschroder M, Pierce AJ, Hollingsworth RE, Tice DA, Michelotti EF.

Mol Cancer Ther. 2015 Jul;14(7):1637-49. doi: 10.1158/1535-7163.MCT-14-1040. Epub 2015 May 6.

14.

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody.

Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM.

MAbs. 2015;7(2):428-39. doi: 10.1080/19420862.2015.1007810.

15.

Bi-epitope SPR surfaces: a solution to develop robust immunoassays.

Peng L, Damschroder MM, Wu H, Dall'Acqua WF.

PLoS One. 2014 Nov 5;9(11):e112070. doi: 10.1371/journal.pone.0112070. eCollection 2014.

16.

Mechanisms of neutralization of a human anti-α-toxin antibody.

Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF.

J Biol Chem. 2014 Oct 24;289(43):29874-80. doi: 10.1074/jbc.M114.601328. Epub 2014 Sep 10.

17.

Current approaches to fine mapping of antigen-antibody interactions.

Abbott WM, Damschroder MM, Lowe DC.

Immunology. 2014 Aug;142(4):526-35. doi: 10.1111/imm.12284. Review.

18.

Structural insights into neonatal Fc receptor-based recycling mechanisms.

Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H, Dall'Acqua WF.

J Biol Chem. 2014 Mar 14;289(11):7812-24. doi: 10.1074/jbc.M113.537563. Epub 2014 Jan 27.

19.

Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia.

Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR.

Antimicrob Agents Chemother. 2014;58(2):1108-17. doi: 10.1128/AAC.02190-13. Epub 2013 Dec 2.

20.

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST.

Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7.

21.

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.

Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, Dall'Acqua W, Damschroder M, Hammond SA.

PLoS One. 2012;7(5):e36412. doi: 10.1371/journal.pone.0036412. Epub 2012 May 4.

22.

Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody.

Peng L, Oganesyan V, Damschroder MM, Wu H, Dall'Acqua WF.

J Mol Biol. 2011 Oct 21;413(2):390-405. doi: 10.1016/j.jmb.2011.08.018. Epub 2011 Aug 16.

PMID:
21867711
23.

B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.

Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ.

J Pharmacol Exp Ther. 2010 Oct;335(1):213-22. doi: 10.1124/jpet.110.168062. Epub 2010 Jul 6. Erratum in: J Pharmacol Exp Ther. 2011 Jan;336(1):294. Dall'Aqua, William [corrected to Dall'Acqua, William].

PMID:
20605905
24.

Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen.

Oganesyan V, Damschroder MM, Phipps S, Wilson SD, Cook KE, Wu H, Dall'Acqua WF.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jun 1;66(Pt 6):730-3. doi: 10.1107/S1744309110015861. Epub 2010 May 29.

25.

MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ.

J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. doi: 10.1016/j.jaci.2010.04.004.

PMID:
20513525
26.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.

Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.

27.

Structural characterization of a human Fc fragment engineered for extended serum half-life.

Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF.

Mol Immunol. 2009 May;46(8-9):1750-5. doi: 10.1016/j.molimm.2009.01.026. Epub 2009 Feb 27.

PMID:
19250681
28.

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon alpha-2A.

Oganesyan V, Damschroder MM, Cook KE, Wu H, Dall'Acqua WF.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Jan 1;65(Pt 1):14-6. doi: 10.1107/S1744309108037925. Epub 2008 Dec 25.

29.

Structural characterization of a mutated, ADCC-enhanced human Fc fragment.

Oganesyan V, Damschroder MM, Leach W, Wu H, Dall'Acqua WF.

Mol Immunol. 2008 Apr;45(7):1872-82.

PMID:
18078997
30.

Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.

Damschroder MM, Widjaja L, Gill PS, Krasnoperov V, Jiang W, Dall'Acqua WF, Wu H.

Mol Immunol. 2007 Apr;44(11):3049-60. Epub 2007 Jan 22.

PMID:
17241664
31.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA.

Mol Cancer Ther. 2006 Dec;5(12):3122-9.

32.

Modulation of the effector functions of a human IgG1 through engineering of its hinge region.

Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H.

J Immunol. 2006 Jul 15;177(2):1129-38.

33.

Antibody humanization by framework shuffling.

Dall'Acqua WF, Damschroder MM, Zhang J, Woods RM, Widjaja L, Yu J, Wu H.

Methods. 2005 May;36(1):43-60.

PMID:
15848074
34.

Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.

Damschroder MM, Kozhich AA, Woods RM, Cheng L, Mullikin BA, Wilson SD, Ulbrandt ND, Bachy CM, Wu H, Suzich JA, Kiener PA, Dall'Acqua WF, White WI.

Mol Immunol. 2004 Aug;41(10):985-1000.

PMID:
15302161
35.

Tissue-specific expression of messenger RNAs encoding endogenous viral superantigens.

Jarvis CD, Germain RN, Hager GL, Damschroder M, Matis LA.

J Immunol. 1994 Feb 1;152(3):1032-8.

PMID:
8301115

Supplemental Content

Loading ...
Support Center